The combination of FDA-approved PIs with a pharmacological IDH2 inhibitor (AGI-6780) triggered synergistic cytotoxicity in MM, MCL, and Burkitt’s lymphoma (BL) cell lines. Here, IDH2 is linked to Burkitt lymphoma.